Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study
about
Immuno-modulatory activity of Ganoderma lucidum-derived polysacharide on human monocytoid dendritic cells pulsed with Der p 1 allergenTreatment of asthma and food allergy with herbal interventions from traditional chinese medicine.Effect of Antiasthma Simplified Herbal Medicine Intervention on neutrophil predominant airway inflammation in a ragweed sensitized murine asthma model.Weight loss herbal intervention therapy (W-LHIT) a non-appetite suppressing natural product controls weight and lowers cholesterol and glucose levels in a murine modelAnti-Asthma Simplified Herbal Medicine Intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon-γ, but not transforming growth factor-β dependentIntegrated traditional Chinese medicine for childhood asthma in Taiwan: a Nationwide cohort study.Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study.Maternal Antiasthma Simplified Herbal Medicine Intervention therapy prevents airway inflammation and modulates pulmonary innate immune responses in young offspring mice.Chinese herbal therapy for the treatment of food allergy.Nonallergen-specific treatments for food allergy.Chinese herbal extracts of Rubia cordifolia and Dianthus superbus suppress IgE production and prevent peanut-induced anaphylaxisComparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial.Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling.Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy.The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged miceGanoderic acid C1 isolated from the anti-asthma formula, ASHMI™ suppresses TNF-α production by mouse macrophages and peripheral blood mononuclear cells from asthma patientsPharmacology and immunological actions of a herbal medicine ASHMI on allergic asthmaThe Flavonoid 7,4'-Dihydroxyflavone Inhibits MUC5AC Gene Expression, Production, and Secretion via Regulation of NF-κB, STAT6, and HDAC2.Glycyrrhiza uralensis flavonoids present in anti-asthma formula, ASHMI™, inhibit memory Th2 responses in vitro and in vivo.Complementary and alternative medicine in pediatric allergic disorders.The anti-asthma herbal medicine ASHMI acutely inhibits airway smooth muscle contraction via prostaglandin E2 activation of EP2/EP4 receptors.Active components of ginger potentiate β-agonist-induced relaxation of airway smooth muscle by modulating cytoskeletal regulatory proteins.Effects and mechanisms of actions of Chinese herbal medicines for asthma.Newer glucocorticosteroids and corticosteroid resistance reversal in asthma.The Immunoregulatory Effects of Traditional Chinese Medicine on Treatment of Asthma or Asthmatic Inflammation.Constituents of the anti-asthma herbal formula ASHMI(TM) synergistically inhibit IL-4 and IL-5 secretion by murine Th2 memory cells, and eotaxin by human lung fibroblasts in vitro.Can we find better bronchodilators to relieve asthma symptoms?The Sophora flavescens flavonoid compound trifolirhizin inhibits acetylcholine induced airway smooth muscle contraction.Integrative Medicine for Respiratory Conditions: Asthma and Chronic Obstructive Pulmonary Disease.Protective effect and molecular mechanism of liquiritin on oxybuprocaine-induced apoptosis of human corneal endothelial cells.Wild Plant-Based Functional Foods, Drugs, and Nutraceuticals
P2860
Q33911650-70AEFF11-B7D6-4506-BE7D-EBFBD724AE30Q33987008-96D76FB1-7B17-435A-AD8B-A88D39780464Q33988560-077CFF78-D3B3-473F-806B-316F6574D170Q34017884-0E8BFF4A-15BC-443D-82AF-A527D42D1175Q34160999-5023174D-FEEC-4B03-9FFC-C9A4059C47B6Q34346301-0A9CB81E-4962-4D6B-B895-CCEFD5CEE4B5Q34519061-2A0227FC-53B6-46CF-B57C-756A1F28F316Q34759202-B579D301-341A-4775-8101-03DA6A7D6E9EQ34770532-4E026C9D-8654-4907-B153-B0B7C2ADEB6EQ34793634-9C44A518-6445-4798-825E-5D1D54F48C69Q35477889-F73A83B4-28ED-4289-B838-ADB2812E3143Q35855681-8BB1151B-D6ED-48E5-9588-62CA87B53538Q35875927-ACB2BD2F-4980-4C4A-951F-F6C8E41628FFQ36144704-F21A0922-2764-4EAA-B21B-7FADFB6FB209Q36170738-E8EBBE24-A231-4EB2-BDF8-62CA43093B00Q36255631-D55EBB68-74E3-494D-B4B9-6E5C049189CCQ36445498-5C881645-64F1-4CD3-BA9E-7D4F8D7E511FQ36445507-ADC96ED7-26E8-48C7-BD4C-8E811B8683DEQ36672693-50DD59BF-0A60-4ABB-BC10-1A07E94C7744Q37405263-5A07AB49-E8F0-4C5D-A72B-80FF3A5BA67CQ37440536-02CC0A77-F662-485C-A96C-10CB1369E67DQ37596098-7EE5B6D3-8908-45F8-A49C-54F294802C28Q37897175-89DC128D-853C-4E05-A91A-D252820AE8E5Q38162976-71CAB4C2-9522-4862-860C-60D2BCA57F12Q38585855-0018BF80-97F4-4401-B1FE-B82A35C56F04Q39143106-E6BDD161-AAB3-47E6-BB03-3BB783DC335EQ39532081-9CA0FDF2-3A5B-43CE-9A43-4B183B1333C8Q42762507-08C45056-2E06-4A0A-BE35-C03316263B4DQ47648795-72EF7FA6-9048-41DD-B9D4-38EF8E785279Q53701720-5C91506D-2A87-4077-B338-E49A29BD5D67Q57614934-D146976A-F6C3-4BC3-A5D5-D5D797D9403D
P2860
Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and tolerability of an ...... dose-escalation phase I study
@ast
Safety and tolerability of an ...... dose-escalation phase I study
@en
type
label
Safety and tolerability of an ...... dose-escalation phase I study
@ast
Safety and tolerability of an ...... dose-escalation phase I study
@en
prefLabel
Safety and tolerability of an ...... dose-escalation phase I study
@ast
Safety and tolerability of an ...... dose-escalation phase I study
@en
P2093
P2860
P356
P1476
Safety and tolerability of an ...... dose-escalation phase I study
@en
P2093
Kristin Kelly-Pieper
Meyer Kattan
Paula Busse
Sangita P Patil
Xiu-Min Li
P2860
P304
P356
10.1089/ACM.2008.0543
P577
2009-07-01T00:00:00Z